PERCECOVAC: Perceptions and Representations of Vaccination Against COVID-19

• Sponsor: Centre Hospitalier Intercommunal Creteil (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT04896957
• Collaborator: Centre Hospitalier Intercommunal Villeneuve Saint Georges (Other)
• Enrollment: 15
• Location: 1
• Anticipated Duration (Months): 12
• Patients Per Site Per Month: 1.3

Study Details

Study Description

Brief Summary

SARS COV2, the virus that causes COVID-19, was first described in Wuhan, China. For this pathology, which causes severe respiratory infections, preventing the transmission of the virus has become fundamental, that is why vaccines have been developed. In France, this vaccination campaign took place in a context where the lack of confidence in vaccination is high:

According to a November 2020 IFOP poll, only 41% of French respondents were willing to be vaccinated against COVID-19.

To our knowledge, there are still few qualitative studies on vaccination on the current issue of vaccination against COVID-19.

Condition or Disease	Intervention/Treatment	Phase
COVID-19 Acute Respiratory Distress Syndrome	Behavioral: Interview

Study Design

• Study Type: Observational
• Anticipated Enrollment: 15 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Perceptions and Representations of Vaccination Against COVID-19
• Actual Study Start Date: Sep 1, 2021
• Anticipated Primary Completion Date: Sep 1, 2022
• Anticipated Study Completion Date: Sep 1, 2022

Outcome Measures

Primary Outcome Measures

1. Perceptions, representations and experiences of Covid-19 vaccination [1 hour]

   Interview based on 6 opened questions

Secondary Outcome Measures

1. Key elements to improve the medical discourse on vaccination [1 hour]

   Interview based on 6 opened questions

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Over 18 years of age

• Patient with a scheduled appointment in consultation or at the vaccination centre

• Not opposed to participation in the protocol

Exclusion Criteria:

• Patient under guardianship or curatorship

• Patient unable to give free and informed consent

• Patient under court protection

• Patient without the cognitive capacity to ensure an interview

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	CHI Villeneuve-Saint-Georges	Villeneuve-Saint-Georges		France

Sponsors and Collaborators

• Centre Hospitalier Intercommunal Creteil
• Centre Hospitalier Intercommunal Villeneuve Saint Georges

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Centre Hospitalier Intercommunal Creteil
• ClinicalTrials.gov Identifier: NCT04896957
• Other Study ID Numbers: PERCECOVAC
• First Posted: May 21, 2021
• Last Update Posted: Nov 23, 2021
• Last Verified: Nov 1, 2021

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Centre Hospitalier Intercommunal Creteil: vaccination perception
• Additional relevant MeSH terms: COVID-19; Respiratory Distress Syndrome; Respiratory Distress Syndrome, Newborn; Acute Lung Injury

Study Results

No Results Posted as of Nov 23, 2021